Nymox's NX-1207 Offers A New And Attractive Approach To The Treatment Of Benign Prostatic Hyperplasia

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) provided an outline of the outstanding potential the Company's proprietary drug, NX-1207, has for the treatment of the common condition of enlarged prostate or benign prostatic hyperplasia (BPH).